Annual Report Overview 2022

By 2030, our knock-your-socks-off KYSO antibody medicinesTM are fundamentally transforming the lives of people with cancer and other serious diseases.

Read our 2022 Annual Report

Read our 2022 Corporate Responsibility Report

Investor Conference Call on FY results/Annual Report 2022

Listen to Webcast


Financial Highlights

Market Cap, DKKb


(2022 year-end market cap)

Revenue, DKKm



2022 Operating Expenses, DKKm


(68% invested in R&D)



“Our 2030 Vision is not a reimagining of what Genmab is, but a bold expansion of what Genmab can be and how we aspire to use our innovation in antibody treatments to fundamentally transform the lives of patients with cancer and other serious diseases.”

Jan G. J. van de Winkel, Ph.D. President & CEO

Financial Review

“As we look back at 2022, the strength of Genmab’s financial profile really stands out. Our strong balance sheet, growing recurring revenues and significant underlying profitability have allowed us, and will continue to allow us, to strategically invest in our business and our pipeline.”

Anthony Pagano, Executive Vice President & Chief Financial Officer

Corporate Governance Report 2022

View Report

Compensation Report 2022

View Report


Genmab is a leading international biotechnology company that creates, develops and commercializes antibody products to transform the treatment of cancer

  • 6

    Approved therapies incorporating Genmab innovation

  • 9

    Genmab-owned ≥50% investigational medicines in clinical development*

    Tisotumab vedotin, epcoritamab, DuoBody®-PD-L1x4-1BB (GEN1046/BNT311), DuoBoday®-CD40x4-1BB (GEN1042/BNT312), DuoHexaBody®-CD37 (GEN3009), HexaBody®-CD38 (GEN3014), DuoBody®-CD3xB7H4 (GEN1047), HexaBody®-CD27 (GEN1053/BNT313), and GEN1056 (BNT322)

  • 4

    Proprietary technology platforms

    DuoBody®, HexaBody®, DuoHexaBody®, HexElect®

  • 40


    Investigational new drug applications (INDs) filed by Genmab and/or partners, based on Genmab’s innovations and technology, since 1999

* As of December 31, 2022: Tisotumab vedotin co-developed with Seagen; epcoritamab co-development with AbbVie; DuoBody®-PD-L1x4-1BB, DuoBody®-CD40x4-1BB, HexaBody®-CD27 and GEN 1056 co-development with BioNTech; Genmab is development HexaBody®-CD38 in an exclusive worldwide license and option agreement with Janssen.

Corporate Social Responsibility

We are committed to being a sustainable, socially responsible biotech company. This commitment is anchored in our vision, core purpose and values, focused for impact through our CSR strategy, and lived every day by our team.

Read our 2022 Corporate Responsibility Report

Get in touch

Contact our media relations team for press inquiries. If you have a general inquiry, please contact the Genmab switchboard at +45 7020 2728. We will handle your personal data in accordance with our Privacy Policy.

  • Marisol Peron

    Senior Vice President,
    Communications and Corporate Affairs

    Telephone: +1 609 524 0065

    777 Scudders Mill Road
    Plainsboro, NJ 08536

  • Andrew Carlsen (for IR)

    Vice President,
    Head of Investor Relations

    Telephone: +45 3377 9558

    Kalvebod Brygge 43
    1560 Copenhagen V

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.